灵麦快讯LMLB125
本周灵麦医药与您分享10大领域，41个欧洲进口仿制药项目
LMC5000469是一家总部位于欧洲的，为创新者和仿制药业提供产品和服务的全球性的制药公司。自其创立开始，其使命就不曾变过，带着巨大的社会使命感，深耕健康行业，致力于提高全球人民的健康水平，为全球人类提供最有效治疗药物来攻克所有的疑难杂症。就是在这样的使命的驱动下，LMC5000469公司现已有多达10多年的仿制药及新药研发的经验，在全球9个国家地区设立了办公室。
然而，作为一个具有社会使命感的天使一样的公司，怎么会忘了14亿的善良有爱的中国人民呢？下个月，LMC5000469大boss即将造访中国！想要合作机会咩~邮件发出来呀: info@lingmed.net.
10大领域41个进口仿制药项目
-
2个项目初步市场分析
表1：消化道及代谢性疾病及抗肿瘤药和免疫机能调节仿制药项目
欲知41个项目的详情，请登录www.lingmed.net/reports下载完整报告
Lingmed European Generic assets feeding involving 10 TAs
This week Lingmed shares with you a set of assets involving 10 Therapeutic areas
LMC5000469 is a pharmaceutical company, headquartered in Spain, which provides products and services to its clients in both the innovator and generic industries. The company’s goal has not changed since day one: combine a healthy growing business with a strong social commitment to improve people’s health and lives. Dedicated to provide patients with the most effective medicine to overcome disease, LMC5000469 had over 10 years’ experience in drug development with 9 offices around the world.
Next Month，the “big boss” of LMC5000469 will come to China looking for partners. Did you want to collaborate with them?
Just call us:021 5386 3003 or email us: info@lingmed.net.
41 Generic assets in 10 therapeutic areas
The initial market analysis for the 2 assets
Table1：Generic assets in Alimentary tract and metabolism and Antineoplastic and immunomodulation agents
For the whole 41 assets, please visit www.lingmed.net/reports
欲知41个项目的详情
请登录 www.lingmed.net/reports
或点击下方“阅读原文”马上下载
